dc.contributor.author | Mureithi Marianne W. | |
dc.contributor.author | Poole, Danielle | |
dc.contributor.author | Naranbhai, Vivek | |
dc.contributor.author | Reddy, Shabashini | |
dc.contributor.author | Mkhwanazi, Nompumelelo P. | |
dc.contributor.author | Sibeko, Sengeziwe | |
dc.contributor.author | Werner, Lise | |
dc.contributor.author | Karim, Quarraisha Abdool | |
dc.contributor.author | Karim, Salim Abdool | |
dc.contributor.author | Ndung’u, Thumbi | |
dc.contributor.author | Altfeld, Marcus | |
dc.contributor.author | The CAPRISA004 Trial Group | |
dc.date.accessioned | 2013-04-24T12:16:19Z | |
dc.date.issued | 2012-06 | |
dc.identifier.citation | J Acquir Immune Defic Syndr. | en |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/22362152 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16596 | |
dc.description.abstract | The Centre for the AIDS Program of Research in South
Africa 004 trial demonstrated reduction of sexual HIV-1 acquisition
in women using a vaginal microbicide containing tenofovir. A better
understanding of the consequences of antiretroviral-containing
microbicides for immune responses in individuals with intercurrent
HIV-1 infection is needed for future trials combining the use of
microbicides with HIV-1 vaccines. Investigation of immune
responses in women who acquired HIV-1 although using tenofovir
gel showed significantly higher (P = 0.01) Gag-specific IFNg+
CD4+ T-cell responses. The use of tenofovir-containing gel around
the time of infection can modulate HIV-1 immunity, and these
immunological changes need to be considered in future trials combining
vaccines and microbicides. | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | Vol. 1;60(2):124-7. (2012); | |
dc.subject | HIV-1 | en |
dc.subject | HIV-1–specific | en |
dc.subject | Vaginal microbicide | en |
dc.subject | Tenofovir | en |
dc.title | Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. | en |
dc.type | Article | en |
local.embargo.terms | 6 months | en |
local.publisher | Department of Medicine. College of Health Sciences. University of Nairobi | en |